Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | HTR1F | P30939 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12345959 | 0.93 | ABL1 (0.52) | ABL1RIN1P2RY6P2RY14POLB | |
| SCHEMBL13722092 | 0.91 | ABL1 (0.52) | ABL1RIN1P2RY6P2RY14POLB | |
| SCHEMBL4773710 | 0.90 | ABL1 (0.54) | ABL1RIN1P2RY6P2RY14POLB | |
| SCHEMBL12408886 | 0.90 | ABL1 (0.51) | ABL1RIN1P2RY6P2RY14POLB | |
| SCHEMBL10072470 | 0.90 | ABL1 (0.51) | ABL1RIN1P2RY6P2RY14POLB | |
| SCHEMBL25629925 | 0.89 | ABL1 (0.52) | ABL1RIN1P2RY6P2RY14POLB | |
| SCHEMBL14929222 | 0.84 | ABL1 (0.42) | ABL1RIN1P2RY6P2RY14POLB | |
| SCHEMBL6879553 | 0.84 | ABL1 (0.58) | ABL1RIN1P2RY6P2RY14POLB | |
| SCHEMBL19814666 | 0.84 | ABL1 (0.42) | ABL1RIN1P2RY6P2RY14POLB | |
| SCHEMBL1096454 | 0.84 | ABL1 (0.42) | ABL1RIN1P2RY6P2RY14POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794499-B2 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES | EXIQON A/S (DK) | 2004-09-21 | — | — | US | disclosed |
| US-20030134808-A1 | Oligonucleotide analogues | WENGEL JESPER (DK) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134808-A1 | Oligonucleotide analogues | TARBP1, DCLRE1B, ADAR | ABL1 4643/4885RIN1 3842/4885P2RY6 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.